

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for June 2025

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Jamp Pharma Corporation	Baclofen Injection USP	Lioresal Intrathecal	BACLOFEN	2 mg/mL	ampoule	02553341
Taro Pharmaceuticals Inc.	Taro-Metformin XR	Glumetza	METFORMIN HCL	500 mg	ER tablet	02552027
Sivem Pharmaceuticals	Mometasone	Nasonex	MOMETASONE FUROATE	50 mcg/ACT	nasal, spray, MD	02551756
Lupin Pharma Canada Limited	Lupin-Tolvaptan	Jinarc	TOLVAPTAN	15 mg & 15 mg	tablet	02557177
Lupin Pharma Canada Limited	Lupin-Tolvaptan	Jinarc	TOLVAPTAN	30 mg & 15 mg	tablet	02557185
Lupin Pharma Canada Limited	Lupin-Tolvaptan	Jinarc	TOLVAPTAN	45 mg & 15 mg	tablet	02557193

Lupin Pharma Canada Limited	Lupin-Tolvaptan	Jinarc	TOLVAPTAN	60 mg & 30 mg	tablet	02557207
Lupin Pharma Canada Limited	Lupin-Tolvaptan	Jinarc	TOLVAPTAN	90 mg & 30 mg	tablet	02557215
Pharmascience Inc.	Pms-Zopiclone	Imovane	ZOPICLONE	3.75 mg	tablet	02458543